COVID-19 Treatment Clinics

These clinics have been launched to help our patients recover safely at home, access outpatient intravenous therapies such as monoclonal antibody treatment when available, and/or receive supportive care in an ambulatory setting as an alternative to an emergency room visit or hospitalization.

The Inova Extended COVID-19 Care Clinics are accepting referrals for patients from all Inova Emergency Rooms, Inova Urgent Care Centers, Inova Primary Care Offices, as well as community practices.

Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful antigens such as viruses. The monoclonal antibody infusions offered specifically target the spike protein of SARS-CoV-2, designed to block the virus’ attachment and entry into human cells.

Infusion treatment – also known as IV therapy – involves administering medications intravenously. This is done by injecting a needle directly into the patient’s arm. This allows for much more efficient treatment since it delivers medicine directly into the bloodstream.

Patients eligible must have experienced symptom onset within the past 10 days, have a positive COVID test, and also meet the following criteria:

Patients 12 or older who weigh at least 40 kg who have the following risk factors:

• Older age (>=65)
• Obesity with a BMI of >=25 for adults or BMI >= 85th percentile for children age 12-17
• Pregnancy
• Chronic kidney disease
• Diabetes
• Immunosuppressive disease or on immunosuppressive treatment
• Cardiovascular disease, including congenital heart disease or hypertension
• Chronic lung disease, including, but not limited to, asthma and COPD
• Sickle cell disease
• Neurodevelopmental disorders (i.e. cerebral palsy) or other conditions that confer medical complexity, such as genetic or metabolic syndromes and severe congenital abnormalities
• Having a medical related technological dependence, i.e. tracheostomy, gastrostomy, or positive pressure ventilation
• Presence of other medical or non-medical risk factors, including race or ethnicity, that may also confer high risk for severe disease.

Providers:

Complete this form to refer a patient.

Patients:

To be referred, please contact your primary care provider.

If you do not have a primary care provider, complete the self-referral form and you will be scheduled for a telemedicine appointment with an Inova Primary Care Provider to see if you qualify for the monoclonal infusion treatment.

Once you have completed the online form, a scheduler will contact you. You can also call 571-472-4502 to schedule your telemedicine assessment appointment.

• Telemedicine assessments
• Monoclonal antibody infusions or other therapies
• On-site, in-person evaluations and supportive care

The monoclonal antibody infusion treatment is currently available by the FDA through Emergency Use Authorization (EUA).

An Emergency Use Authorization (EUA) is a mechanism to facilitate the availability and use of medical countermeasures, including vaccines, during public health emergencies, such as the current COVID-19 pandemic.

The most common side effect shown in studies has been nausea. This medication has been very well tolerated. Nevertheless, Inova providers will be closely monitoring you for 1 hour after treatment to ensure your safety.

There have not been any studies on pregnant patients. Given the low risk associated with this medication, pregnant patients can receive the treatment if requested.

The cost of any telemedicine visits or infusion fee are covered by Medicare, Medicaid, and commercial insurance. Co-pays may apply. The infusion and telemedicine visits are available to the uninsured who can apply for financial assistance.

Inova is not charging for the COVID-19 infusion treatment, but will charge for administering the medication. Charges will vary depending on your coverage.

Uninsured patients can apply for financial assistance. Financial assistance coverage will depend on qualifications.